Filing Details

Accession Number:
0001140361-18-023077
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-05-11 17:00:48
Reporting Period:
2018-05-09
Accepted Time:
2018-05-11 17:00:48
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1435049 Aduro Biotech Inc. ADRO () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1193201 T Stephen Isaacs C/O Aduro Biotech, Inc.
740 Heinz Avenue
Berkeley CA 94710
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-05-09 5,688 $0.82 211,434 No 4 M Direct
Common Stock Acquisiton 2018-05-09 34,312 $1.00 245,746 No 4 M Direct
Common Stock Disposition 2018-05-09 40,000 $8.01 205,746 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2018-05-09 5,688 $0.00 5,688 $0.82
Common Stock Stock Option (right to buy) Disposition 2018-05-09 34,312 $0.00 34,312 $1.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2023-11-26 No 4 M Direct
866,479 2024-07-30 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 8,932 Indirect By Family Trust
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2017.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.95 to $8.125, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. The shares owned directly by the Isaacs-MacBride Family Trust UAD 03/09/01, for which the Reporting Person is a trustee.
  4. The shares subject to the Option are fully vested and immediately exercisable.
  5. The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of July 31, 2014.